World Wires · story 5527 · unverified · 1 source(s)

Moleculin completes Part A enrollment in Phase 2/3 AML trial

Moleculin Biotech completed enrollment for Part A of its Phase 2/3 MIRACLE trial evaluating Annamycin for acute myeloid leukemia.

Open in the desk

Coverage

• Moleculin completes Part A enrollment in Phase 2/3 AML trial GlobeNewswire: public companies · tier D · clear net · 2026-09-29 12:45 UTC

What this site indexes